| 01 June 2018

ERN-EYE Launch Short Term Medical Trainee Programme

This year, ERN-EYE will award four grants to medical trainees, medical specialists, or health professionals who belong to one of the 29 ERN-EYE members and who want to improve their knowledge in the field of rare eye diseases through a short stay in one of another ERN-EYE member HCPs

ERN-EYE will reimburse travel & accommodation costs for one week exchange up to a ceiling of 1250€

For Further information log onto https://www.ern-eye.eu/ern-eye-short-term-exchange-program

| 10 October 2017

Industry News: Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

Novartis has reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These pivotal studies enrolled more than 1,800 patients with neovascular age-related macular degeneration (nAMD) across 400 centres worldwide.

| 02 October 2017

World Retina Day 2017 - Brasil

No Dia Mundial da Retina, sábado, 30 de setembro de 2017, a Retina Internacional, a Retina Brasil e  outras 40 organizações associadas, estão  lançando o ALERTA DAS DOENÇAS  OCULARES RARAS  para as entidades a ela ligadas, de caráter nacional ou regional.

Entendemos que chegou a hora de lutar  de  forma efetiva para que haja acesso de todos aos serviços de genotipagem para doenças hereditárias da retina e para as doenças oculares raras.

| 12 July 2017

SparingVision Wins Grand Prize of 2017 i-Lab Contest for New, Innovative French Companies


Bpifrance and Foundation Fighting Blindness have launched SparingVision to develop vision-saving treatment for Inherited Retinal Diseases. The newly established French company, SparingVision has won the 2017 i-Lab Grand Prize recognizing new and innovative companies. The i-Lab competition is organized by the French Ministry of Higher Education, Research and Innovation and Bpifrance (BPI).

| 06 July 2017

Industry News: Drug Candidate for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

ProQR Therapeutics N.V. has announced that the company’s investigational drug QRX-411 has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is the leading cause of combined deafness and blindness due to genetic defects in the Usher gene.

| 10 April 2017

Retina 2018 New Zealand


Report by Fraser Alexander, Local Organising Committee

On behalf of Retina International and the Local Organising committee for Retina 2018 New Zealand, I welcome you to the 20th Retina International world congress – to be held in New Zealand for the first time on February 10  and 11, 2018.

| 03 July 2016

Retina International Constitution

Retina International, formerly the International Retinitis Pigmentosa Association (IRPA), is a voluntary, charitable “umbrella association of national societies each of which is formed by people with a Retinal Dystrophy such as Retinitis Pigmentosa (RP), Usher Syndrome, Macular Degeneration (MD) and other allied retinal dystrophies, their families and friends.”

NOTE: The laws of some countries do not allow for charitable status; in such cases it must be clear that the society has charitable purposes and is not run for profit


Join Our Mailing List